We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+11.44%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
-$4.88M
Cap. Flow
-$2.83M
Cap. Flow %
-6.15%
Top 10 Hldgs %
52.4%
Holding
53
New
2
Increased
15
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.14M
2
LITS
Lite Strategy Inc
LITS
+$1.23M
3
EXEL icon
Exelixis
EXEL
+$280K
4
INCY icon
Incyte
INCY
+$71.3K
5
ALKS icon
Alkermes
ALKS
+$55.5K

Top Sells

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.11M
2
NKTR icon
Nektar Therapeutics
NKTR
+$1.15M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$671K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$382K
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$281K

Sector Composition

Rank Sector Weight
1 Healthcare 71.92%
2 Miscellaneous 28.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
51
PUT
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
– –
-60,000
Closed -$3.3M
KPTI icon
52
Karyopharm Therapeutics
KPTI
$44M
– –
-3,333
Closed -$671K
AVXS
53
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-2,275
Closed -$281K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opus Point Partners Management held 53 positions worth $46.1M, down 9.6% from $51M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opus Point Partners Management withdrew a net $2.83M in Q2 2018, closing 3 positions and reducing 16 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $671K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 65% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Lite Strategy Inc worth $1.58M.

  • Opus Point Partners Management's largest Q2 2018 buy was Lite Strategy Inc: 20,000 shares worth $1.58M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q2 2018, an estimated $3.14M increase.
  • Opus Point Partners Management's biggest Q2 2018 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $5.11M.
  • Opus Point Partners Management fully exited Karyopharm Therapeutics in Q2 2018, selling an estimated $671K.
  • Opus Point Partners Management's ten largest holdings make up 52% of its $46.1M portfolio in Q2 2018.
  • Opus Point Partners Management opened 2 new positions and closed 3 in Q2 2018.
  • Opus Point Partners Management's portfolio value fell 9.6% quarter-over-quarter to $46.1M.

Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.